{"id":129138,"date":"2026-09-10T23:39:21","date_gmt":"2026-09-10T23:39:21","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/129138\/"},"modified":"2026-09-10T23:39:21","modified_gmt":"2026-09-10T23:39:21","slug":"novartis-rebounds-as-30-billion-wipeout-draws-board-challenge-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/129138\/","title":{"rendered":"Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This article first appeared on <a href=\"https:\/\/www.gurufocus.com\/news\/9075584\/novartis-rebounds-as-30-billion-wipeout-draws-board-challenge?utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;r=caf6fe0e0db70d936033da5461e60141\" data-ylk=\"slk:GuruFocus;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;GuruFocus&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">GuruFocus<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novartis (<a href=\"https:\/\/finance.yahoo.com\/quote\/NVS\" data-ylk=\"slk:NYSE%3ANVS;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;NYSE:NVS&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" class=\"stocks_tp\" rel=\"nofollow noopener\">NYSE:NVS<\/a>), the Swiss pharmaceutical group, <a href=\"https:\/\/www.reuters.com\/world\/major-novartis-shareholder-calls-board-shake-up-after-drug-trial-setbacks-2026-09-10\/\" data-ylk=\"slk:rebounded;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;rebounded&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">rebounded<\/a> 0.8% to $138.545 Thursday as a major investor pushed for tougher boardroom oversight. Artisan Partners&#8217; David Samra wants Novartis to strengthen its acquisition review process and establish a dedicated board committee to challenge major transactions before billions of dollars are committed.  <\/p>\n<p>        <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/d2dced890197e4640b026b67a599d1f4b1110843b1a48bbc9e40aba0ea5d1453\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fuserupload.gurufocus.com%2F2098061907327098880.png\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge\" height=\"540\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> <a href=\"https:\/\/www.gurufocus.com\/term\/gf-value\/NVS?r=caf6fe0e0db70d936033da5461e60141&amp;utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;utm_content=novartis_rebounds_as_%2430_billion_wipeout_draws_board_challenge&amp;utm_term=NVS\" data-ylk=\"slk:NVS%20GF%20Value%20chart;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;NVS GF Value chart&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">NVS GF Value chart<\/a>           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The pressure arrived after two clinical disappointments helped trigger a record one-day stock plunge of more than 10%, wiping out nearly $30 billion in market value. Del-desiran, obtained through the $12 billion Avidity acquisition, missed its late-stage trial goal. Samra also questioned compensation measures that exclude writedowns, although he praised CEO Vas Narasimhan&#8217;s handling of the underlying business. Novartis stood by its guidance, pipeline and approach to capital allocation.  <\/p>\n<p>    <a href=\"https:\/\/www.gurufocus.com\/stock\/NVS\/summary?search=Novartis&amp;r=9e8553cee17e7be6cdee2cf7b0a937b5&amp;r=caf6fe0e0db70d936033da5461e60141&amp;utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;utm_content=novartis_rebounds_as_%2430_billion_wipeout_draws_board_challenge&amp;utm_term=NVS\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge\" height=\"540\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge  \u00b7 us.finance.gurufocus         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The $12 billion Avidity purchase equals roughly 2.2 times Novartis&#8217;s latest quarterly <a href=\"https:\/\/www.novartis.com\/news\/media-releases\/novartis-delivered-sales-growth-q2-and-further-advanced-pipeline-full-year-guidance-reaffirmed\" data-ylk=\"slk:free%20cash%20flow;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;free cash flow&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">free cash flow<\/a> and about 83% of quarterly revenue. The picture adds a valuation warning: the $138.545 share price sits 5.81% above the $130.94 GF Value estimate. Other acquired drugs could still deliver returns, but the shareholder challenge cuts deeperwhether the board is skeptical enough before placing enormous bets on uncertain clinical assets.  <\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Novartis (NYSE:NVS), the Swiss pharmaceutical group, rebounded 0.8% to $138.545 Thursday as&hellip;\n","protected":false},"author":2,"featured_media":129139,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[62774,62773,3275,206,62858],"class_list":["post-129138","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-artisan-partners","tag-david-samra","tag-gurufocus","tag-novartis","tag-pharmaceutical-group"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117249387142275138","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/129138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=129138"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/129138\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/129139"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=129138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=129138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=129138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}